全部照片(1)
About This Item
經驗公式（希爾表示法）:
C19H22F2N4O3
CAS號碼:
分子量：:
392.40
Beilstein:
9170271
MDL號碼:
分類程式碼代碼:
51282944
PubChem物質ID:
NACRES:
NA.85
推薦產品
生物源
synthetic
化驗
≥98.0% (HPLC)
形狀
powder
顏色
white to light yellow
抗生素活性譜
Gram-negative bacteria
Gram-positive bacteria
mycobacteria
mycoplasma
作用方式
enzyme | inhibits
SMILES 字串
C[C@H]1CN(C[C@@H](C)N1)c2c(F)c(N)c3C(=O)C(=CN(C4CC4)c3c2F)C(O)=O
InChI
1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
InChI 密鑰
DZZWHBIBMUVIIW-DTORHVGOSA-N
基因資訊
human ... KCNH1(3756) , TOP2A(7153)
尋找類似的產品？ 前往 產品比較指南
應用
Sparfoxacin is used to study antimicrobial activity against Mycobacteria and respiratory tract infections .
生化／生理作用
Sparfloxacin fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and/or topoisomerase IV. It inhibits bacterial DNA gyrase-dependent processes such as DNA polymerization, ATP-dependent-DNA supercoiling, and chromosome fragmentation.
包裝
1g, 10g
其他說明
Keep container tightly closed in a dry and well-ventilated place. Keep in a dry place.Storage class (TRGS 510): Non Combustible Solids
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
客戶也查看了
K L Goa et al.
Drugs, 53(4), 700-725 (1997-04-01)
Sparfloxacin is a fluoroquinolone antibacterial agent with activity against a broad range of Gram-negative and Gram-positive organisms including Streptococcus pneumoniae, one of the main pathogens in community-acquired pneumonia. In this infection, sparfloxacin has shown efficacy similar to that of amoxicillin
N Rastogi et al.
Antimicrobial agents and chemotherapy, 35(12), 2473-2480 (1991-12-01)
The MICs and MBCs of the new difluorinated quinolone drug sparfloxacin against type strains belonging to 21 species of mycobacteria were screened. The MICs and MBCs were within the range of 0.1 to 2.0 and 0.1 to 4.0 micrograms/ml, respectively
Radha K Shandil et al.
Antimicrobial agents and chemotherapy, 51(2), 576-582 (2006-12-06)
Members of the fluoroquinolone class are being actively evaluated for inclusion in tuberculosis chemotherapy regimens, and we sought to determine the best in vitro and pharmacodynamic predictors of in vivo efficacy in mice. MICs for Mycobacterium tuberculosis H37Rv were 0.1
Stéphanie Arsène et al.
Antimicrobial agents and chemotherapy, 51(9), 3254-3258 (2007-07-11)
Fluoroquinolones are poorly active against enterococci. Recently, plasmid-borne resistance to fluoroquinolones due to the qnr gene was reported in members of the Enterobacteriaceae family. The gene encodes a pentapeptide repeat protein that protects DNA gyrase from inhibition by fluoroquinolones. We
Joëlle Azéma et al.
Bioorganic & medicinal chemistry, 17(15), 5396-5407 (2009-07-15)
Ciprofloxacin (CP), an antibiotic has been shown to have antiproliferative and apoptotic activities in several cancer cell lines. Moreover, several reports have highlighted the interest of increasing the lipophilicity to improve the antitumor efficacy. These studies have led us to
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務